Mirum Pharmaceuticals price target raised to $152 from $137 at Morgan Stanley
Morgan Stanley raised its price target for Mirum Pharmaceuticals (MIRM) to $152 from $137, citing positive Phase 3 study data and increased confidence in $1B peak sales for Livmarli. Micron (MU) shares fell 4% amid competition concerns, but Cavenagh Research upgraded it to Strong Buy with a $2,577 target, citing contractual pricing protections and strong financial results.
How this was made
The 30-second read
Why it matters
The price target increase signals higher upside for Mirum, while the Micron section adds no actionable insight for that ticker.
Market read
Analyst upgrade provides a fresh catalyst for Mirum, potentially prompting short-term buying.
What to watch
Potential competition and reimbursement uncertainty could limit sales.
Background
The article combines a new analyst price target for Mirum with a lengthy commentary on Micron, but only Mirum is the primary subject.
Ticker impact
Morgan Stanley raised Mirum Pharmaceuticals' price target to $152 from $137, indicating increased confidence after positive Phase 3 data.
likely upward pressure as investors price in higher target and growth expectations
The new target reflects confidence in a $1B peak sales opportunity and positive trial data, which can attract buying.
Market effects
Positive sentiment may spill over to other biotech firms with late-stage trials.
U.S. biotech sector could see modest gains.
Limited to investors tracking biotech pipelines.
Counterpoint
The target raise may be premature if Phase 3 data faces regulatory hurdles.
Key entities
- companyMirum Pharmaceuticals
Biotech firm with positive Phase 3 EXPAND study results.
